Dear Colleagues,

Despite the significant advances in cancer treatment attained in recent years, challenges such as drug resistance and adverse side effects continue to plague the therapeutic efforts. Nevertheless, the incorporation of immunomodulators stands out to be a promising strategy for enhancing the efficacy and safety of conventional cancer treatments. The objective of this special issue is to explore the potential of immunomodulators as adjuvant therapies to improve cancer outcomes.

This special issue welcomes submissions that examine the mechanisms influencing immunological pathways and enhancing anti-tumor immunity. Additionally, we invite contributions that examine the potential of immunomodulatory compounds that act synergistically with standard cancer therapies. Topics of interest include, but are not limited to, the identification of novel immunomodulators, their effects on immune cells and immune-related mechanisms (e.g., inflammatory markers), and translational studies evaluating their therapeutic potential. By convening leading experts in this field, this special issue is primed to advance our understanding of how to effectively enhance immune response by incorporating immunomodulators into standard cancer treatment regimens.

Dr. Yamixa Delgado
Guest Editor